Research programme: glucagon and glucagon-like peptide-1 agonists - Arecor

Drug Profile

Research programme: glucagon and glucagon-like peptide-1 agonists - Arecor

Alternative Names: Aqueous Liraglutide - Arecor; Liraglutide - Arecor; Stable aqueous glucagon - Arecor

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Arecor
  • Class Glucagon-like peptides; Peptide hormones; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 15 Sep 2016 Preclinical trials in Diabetes mellitus in United Kingdom (Parenteral) before September 2016 (Arecor pipeline, September 2016)
  • 15 Sep 2016 Arecor has patent protection for aqueous glucagon in (Arecor pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top